TABLE 3.
Baseline characteristics of stage IV adenocarcinoma patients according to sex during 2014 to 2017
| Total | Male | Female | p value | |
|---|---|---|---|---|
| No. of patients | 2433 | 1469 | 964 | |
| Age (years) | 67.0 (58.0–75.0) | 67.0 (59.0–74.0) | 69.0 (58.0–77.0) | 0.036 |
| Ever‐smoker | 1258 (51.7%) | 1177 (80.1%) | 81 (8.4%) | <0.001 |
| BMI (kg/m2) | 23.0 (22.3–23.9) | 23.2 (22.2–24.3) | 22.8 (21.9–24.2) | 0.636 |
| Symptoms | 2392 | 1445 | 947 | |
| Asymptomatic | 221 (9.2%) | 122 (8.4%) | 99 (10.5%) | 0.099 |
| Cough | 880 (36.8%) | 517 (35.8%) | 363 (38.3%) | 0.216 |
| Sputum | 446 (18.6%) | 287 (19.9%) | 159 (16.8%) | 0.058 |
| Dyspnea | 617 (25.8%) | 368 (25.5%) | 249 (26.3%) | 0.666 |
| Hoarseness | 47 (2.0%) | 35 (2.4%) | 12 (1.3%) | 0.046 |
| Hemoptysis | 104 (4.3%) | 74 (5.1%) | 30 (3.2%) | 0.022 |
| Weight loss | 188 (7.9%) | 116 (8.0%) | 72 (7.6%) | 0.699 |
| Pain | 714 (29.8%) | 455 (31.5%) | 259 (27.3%) | 0.030 |
| Performance status | 1795 | 1099 | 696 | 0.341 |
| 0–1 | 1500 (83.6%) | 916 (83.3%) | 584 (83.9%) | |
| 2–4 | 295 (16.4%) | 183 (16.7%) | 112 (16.1%) | |
| EGFR mutation | 2433 | 1469 | 964 | <0.001 |
| Positive | 842 (34.6%) | 349 (23.8%) | 493 (51.1%) | |
| Negative | 1336 (54.9%) | 955 (65.0%) | 381 (39.5%) | |
| Not tested | 255 (10.5%) | 165 (11.2%) | 90 (9.3%) | |
| ALK | 2433 | 1469 | 964 | 0.005 |
| Positive | 185 (7.6%) | 93 (6.3%) | 92 (9.5%) | |
| Negative | 1599 (65.7%) | 963 (65.6%) | 636 (66.0%) | |
| Not tested | 649 (26.7%) | 413 (28.1%) | 236 (24.5%) |
Note: Values are presented as mean ± standard deviation, median (interquartile range), or number (%), unless otherwise indicated.
Abbreviations: ALK, anaplastic lymphoma kinase; BMI, body mass index; EGFR, epidermal growth factor receptor.